TP53 and plasma cell myeloma: It has been discovered that CRBN is required for the anti-myeloma activity of IMiDs19,50 but IMiDs cannot improve the overall survival of multiple myeloma patients with p53 deficiency51, indicating the possible molecular linkage between CRBN and p53.